JP2021063129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021063129A5 JP2021063129A5 JP2021003152A JP2021003152A JP2021063129A5 JP 2021063129 A5 JP2021063129 A5 JP 2021063129A5 JP 2021003152 A JP2021003152 A JP 2021003152A JP 2021003152 A JP2021003152 A JP 2021003152A JP 2021063129 A5 JP2021063129 A5 JP 2021063129A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- seq
- antibody
- constant region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010062016 Immunosuppression Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023110414A JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| US62/192,269 | 2015-07-14 | ||
| US201562197966P | 2015-07-28 | 2015-07-28 | |
| US62/197,966 | 2015-07-28 | ||
| US201662277201P | 2016-01-11 | 2016-01-11 | |
| US62/277,201 | 2016-01-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Division JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023110414A Division JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021063129A JP2021063129A (ja) | 2021-04-22 |
| JP2021063129A5 true JP2021063129A5 (cg-RX-API-DMAC7.html) | 2021-06-10 |
Family
ID=57757587
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Active JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Active JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Country Status (22)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297907B2 (en) * | 2015-07-14 | 2024-07-01 | Immunext Inc | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
| JP7256011B2 (ja) | 2015-11-27 | 2023-04-11 | アブリンクス エン．ヴェー． | Ｃｄ４０ｌを阻害するポリペプチド |
| WO2019195770A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| WO2020068723A1 (en) * | 2018-09-24 | 2020-04-02 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN115227824A (zh) * | 2018-11-12 | 2022-10-25 | 中南大学湘雅二医院 | 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用 |
| US20220185785A1 (en) * | 2019-04-12 | 2022-06-16 | TONIX Pharmaceuticals Holding Corp | Inhibitors of cd40-cd154 binding |
| AU2020358854A1 (en) * | 2019-10-03 | 2022-05-26 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| CN113488170B (zh) * | 2021-07-02 | 2023-07-25 | 温州医科大学 | 急性前葡萄膜炎复发风险预测模型构建方法及相关设备 |
| JP2024527947A (ja) * | 2021-07-30 | 2024-07-26 | ソウル ナショナル ユニバーシティ アールアンドディービー ファウンデーション | 抗ｃｄ１５４抗体及びその用途 |
| CN117715941A (zh) * | 2021-07-30 | 2024-03-15 | 首尔大学校产学协力团 | 抗cd154抗体及其用途 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024222895A1 (zh) * | 2023-04-28 | 2024-10-31 | 信达生物制药(苏州)有限公司 | 抗cd40l抗体及其在人自身免疫疾病治疗的应用 |
| US20240392022A1 (en) | 2023-05-22 | 2024-11-28 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd40l antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110855A (en) | 1993-09-02 | 1999-04-11 | Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6444018B1 (en) | 1998-06-25 | 2002-09-03 | Xerox Corporation | Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| WO2002030986A2 (en) | 2000-10-13 | 2002-04-18 | Biogen, Inc. | HUMANIZED ANTI-LT-β-R ANTIBODIES |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| AU2004253868B2 (en) | 2003-06-13 | 2011-06-16 | Biogen Ma Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
| EP2502935B1 (en) | 2003-08-22 | 2017-03-29 | Biogen MA Inc. | Improved antibodies having altered effector function and methods for making the same |
| WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| JP5721951B2 (ja) * | 2007-03-22 | 2015-05-20 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用 |
| US8852597B2 (en) * | 2011-04-04 | 2014-10-07 | The Trustees Of Dartmouth College | Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| IL297907B2 (en) * | 2015-07-14 | 2024-07-01 | Immunext Inc | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
-
2016
- 2016-07-13 IL IL297907A patent/IL297907B2/en unknown
- 2016-07-13 JP JP2018521475A patent/JP6826113B2/ja active Active
- 2016-07-13 EA EA201890297A patent/EA201890297A1/ru unknown
- 2016-07-13 MY MYPI2020006781A patent/MY203911A/en unknown
- 2016-07-13 AU AU2016294417A patent/AU2016294417B2/en active Active
- 2016-07-13 TN TNP/2018/000021A patent/TN2018000021A1/en unknown
- 2016-07-13 CR CR20180097A patent/CR20180097A/es unknown
- 2016-07-13 MY MYPI2018700104A patent/MY196991A/en unknown
- 2016-07-13 EP EP16825103.1A patent/EP3331548A4/en active Pending
- 2016-07-13 WO PCT/US2016/042074 patent/WO2017011544A1/en not_active Ceased
- 2016-07-13 KR KR1020257020732A patent/KR20250099272A/ko active Pending
- 2016-07-13 PE PE2018000072A patent/PE20180741A1/es unknown
- 2016-07-13 CN CN202210146798.5A patent/CN114671952A/zh active Pending
- 2016-07-13 HK HK18109202.5A patent/HK1249735A1/zh unknown
- 2016-07-13 IL IL310460A patent/IL310460A/en unknown
- 2016-07-13 SG SG10201913431QA patent/SG10201913431QA/en unknown
- 2016-07-13 US US15/744,379 patent/US10874738B2/en active Active
- 2016-07-13 KR KR1020187004571A patent/KR102825142B1/ko active Active
- 2016-07-13 CN CN201680053004.3A patent/CN108135969B/zh active Active
- 2016-07-13 MX MX2018000548A patent/MX2018000548A/es unknown
- 2016-07-13 IL IL256800A patent/IL256800B2/en unknown
-
2018
- 2018-01-11 PH PH12018500098A patent/PH12018500098A1/en unknown
- 2018-01-12 CL CL2018000103A patent/CL2018000103A1/es unknown
- 2018-01-12 GT GT201800018A patent/GT201800018A/es unknown
- 2018-01-12 DO DO2018000018A patent/DOP2018000018A/es unknown
- 2018-01-12 MX MX2023014921A patent/MX2023014921A/es unknown
- 2018-02-09 EC ECIEPI20189949A patent/ECSP18009949A/es unknown
- 2018-02-12 CO CONC2018/0001363A patent/CO2018001363A2/es unknown
-
2020
- 2020-11-23 US US17/101,139 patent/US11596689B2/en active Active
-
2021
- 2021-01-13 JP JP2021003152A patent/JP2021063129A/ja active Pending
-
2022
- 2022-11-02 AU AU2022263520A patent/AU2022263520B2/en active Active
-
2023
- 2023-02-01 US US18/162,769 patent/US20240000929A1/en active Pending
- 2023-07-05 JP JP2023110414A patent/JP7605914B2/ja active Active
-
2024
- 2024-12-12 JP JP2024217195A patent/JP2025038055A/ja active Pending
-
2025
- 2025-09-05 AU AU2025226796A patent/AU2025226796A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063129A5 (cg-RX-API-DMAC7.html) | ||
| US12116405B2 (en) | Arthritis treatment | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| TW201024318A (en) | Isolation and purification of antibodies using protein A affinity chromatography | |
| JP2020073499A (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| JP2019525730A (ja) | 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び用途 | |
| TW201030016A (en) | Antibodies that bind to IL-18 and methods of purifying the same | |
| TW202206462A (zh) | 具有經修飾重鏈恆定區之多特異性重鏈抗體 | |
| TW201031421A (en) | IL-1 binding proteins | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| CN110662768A (zh) | 治疗性抗cd40配体抗体 | |
| CN105358575B (zh) | 干扰素α和ω抗体拮抗剂 | |
| JPWO2020018503A5 (cg-RX-API-DMAC7.html) | ||
| US20060188505A1 (en) | Treatment of autism | |
| JP2022517809A (ja) | Ｌｉｌｒｂ３結合分子とその使用 | |
| JP7696291B2 (ja) | 抗ｉｌ‐１７ａ抗体及びその適用 | |
| JP7783183B2 (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 | |
| AU2017200039B2 (en) | Arthritis treatment | |
| BR122025021892A2 (pt) | Células hospedeiras |